Mabion S.A. Logo

Mabion S.A.

Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.

MAB | WAR

Overview

Corporate Details

ISIN(s):
PLMBION00016 (+1 more)
LEI:
259400KG5JVQPPZL6X53
Country:
Poland
Address:
Konstantynów Łódzki GEN. MARIANA LANGIEWICZA 60, 95-050 Konstantynów Łódzki
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mabion S.A. is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services to pharmaceutical and biotech companies globally. The company specializes in the development, analytics, and manufacturing of complex biologic drugs. Mabion leverages advanced statistical methodologies, such as Design of Experiments (DoE), to optimize bioprocesses, enhance product quality, and ensure regulatory compliance. This data-driven approach supports accelerated development timelines and efficient, robust manufacturing for its partners, demonstrated through its involvement in large-scale production projects for biologics and vaccine components.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-17 14:10
Regulatory News Service
Załącznik 2_Strategia ESG Mabion S.A.
Polish 11.7 MB
2025-11-17 14:10
Regulatory News Service
Załącznik 1_Strategia Mabion S.A.
Polish 1.4 MB
2025-11-17 14:10
Management Discussion and Analysis
Przyjęcie Strategii Spółki Mabion S.A. na lata 2025 - 2030 oraz ujawnienie opóź…
English 8.3 KB
2025-11-17 14:10
Management Discussion and Analysis
Przyjęcie Strategii Spółki Mabion S.A. na lata 2025 - 2030 oraz ujawnienie opóź…
Polish 8.8 KB
2025-10-24 20:35
Related Party Transaction
Zawarcie z Twiti Investments Ltd. umowy pożyczki - Content (EN)
English 2.5 KB
2025-10-24 20:35
Capital/Financing Update
Zawarcie z Twiti Investments Ltd. umowy pożyczki - Content (PL)
Polish 2.4 KB
2025-10-08 15:16
Audit Report / Information
Informacja dotycząca stanowiska Zarządu i opinii Rady Nadzorczej Mabion S.A. od…
Polish 264.8 KB
2025-10-08 15:16
Interim Report
Raport Biegłego Rewidenta
Polish 497.9 KB
2025-10-08 15:16
Interim Report
Oświadczenie Zarządu w sprawie rzetelności sporządzenia sprawozdania finansowego
Polish 228.5 KB
2025-10-08 15:16
Management Discussion and Analysis
Mabion_Sprawozdanie Zarządu_1H2025
Polish 3.2 MB
2025-10-08 15:16
Interim Report
Mabion MSSF_1H2025
Polish 3.4 MB
2025-10-08 15:16
Audit Report / Information
Stanowisko Zarządu i opinia Rady Nadzorczej Mabion S.A. odnoszące się do odmowy…
Polish 368.1 KB
2025-10-08 14:27
Audit Report / Information
Stanowisko Zarządu i opinia Rady Nadzorczej Mabion S.A. odnoszące się do odmowy…
Polish 368.1 KB
2025-10-08 14:27
Audit Report / Information
Uzupełnienie raportu okresowego Spółki za I półrocze 2025 roku - Content (EN)
English 1.0 KB
2025-10-08 14:27
Report Publication Announcement
Uzupełnienie raportu okresowego Spółki za I półrocze 2025 roku - Content (PL)
Polish 784 bytes

Automate Your Workflow. Get a real-time feed of all Mabion S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mabion S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mabion S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VivoSim Labs, INC. Logo
Offers 3D human tissue models for predictive toxicology testing to accelerate drug discovery.
United States of America
VIVS
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea
082800
VOLITIONRX LTD Logo
Develops epigenetic blood tests for early cancer and sepsis detection in human/veterinary markets.
United States of America
VNRX
vTv Therapeutics Inc. Logo
Develops oral small molecule drugs for type 1 diabetes and other chronic conditions.
United States of America
VTVT
VYNE Therapeutics Inc. Logo
Clinical-stage biopharma developing novel therapies for immuno-inflammatory diseases.
United States of America
VYNE
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan
4512
Wave Life Sciences Ltd. Logo
Developing RNA-based medicines for severe genetic diseases like DMD and Huntington's disease.
United States of America
WVE
WELLBIOTEC CO.,LTD Logo
Diversified in biopharma, EV chargers, and lithium supply for batteries.
South Korea
010600
Werewolf Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies for a localized immune attack on cancer.
United States of America
HOWL
WHANIN PHARM CO.,LTD Logo
Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.
South Korea
016580

Talk to a Data Expert

Have a question? We'll get back to you promptly.